Business context and reporting period
The supplied filing is Adtalem Global Education Inc.’s Form 10-Q for the three months ended September 30, 2022 (first quarter of fiscal 2023), filed November 3, 2022. It does not appear to be a filing for “Covista Inc.” or calendar 2022 Q1; verify the issuer and period before relying on this summary. Adtalem reported continuing operations across Chamberlain, Walden, and Medical and Veterinary after divesting its Financial Services businesses.
Financial and operating results
Amounts below are in millions of dollars unless stated otherwise.
| Metric | Quarter ended Sep. 30, 2022 | Prior-year quarter |
|---|---|---|
| Revenue | $354.6 | $289.1 |
| Operating income (loss) | $23.1 | $(22.1) |
| Continuing-operations income (loss) | $5.8 | $(77.2) |
| Net income (loss) | $2.2 | $(58.0) |
| Diluted EPS | $0.05 | $(1.17) |
| Operating cash flow, continuing operations | $91.5 | $29.5 |
| Capital expenditures | $5.6 | $6.7 |
- Revenue rose 22.7% as reported, primarily because Walden was included for a full quarter versus only part of the prior-year quarter. Excluding acquisition timing, revenue grew 0.5%.
- Consolidated GAAP operating margin was 6.5%, versus negative 7.6%. Adjusted operating income, a non-GAAP measure, was $65.1 million, up 78.7%; adjusted operating margin was 18.4%, versus 12.6%.
- Segment revenue: Chamberlain $135.4 million (down 0.2%); Walden $130.9 million (up 90.8% reported, down 2.7% excluding acquisition timing); Medical and Veterinary $88.3 million (up 4.1%). Adjusted segment operating income was $27.0 million, $23.4 million, and $17.4 million, respectively.
- Cash and cash equivalents were $327.5 million at September 30, 2022; restricted cash was $2.5 million. Current assets were $569.9 million and current liabilities $490.5 million.
- Debt principal was $758.3 million: $405.0 million of 5.50% secured notes due 2028 and $353.3 million of Term Loan B. The term loan rate was 7.05%. The $400 million revolving facility was undrawn and fully available. The company reported compliance with debt covenants.
- Total assets were $3.00 billion and shareholders’ equity $1.51 billion. Operating lease liabilities totaled $214.9 million.
Changes versus the prior comparable period
- Results improved sharply from the prior-year GAAP operating and net losses. Management attributed the change primarily to lower interest expense and acquisition/integration expense, as well as the timing of Walden’s acquisition; prior-year results also included Walden purchase-accounting and CEO transition costs.
- Interest expense declined to $17.8 million from $47.4 million. Prior-year costs included issuance-cost write-offs, bridge financing fees, and termination of an interest-rate swap. Current-quarter interest expense included a $2.9 million write-off of loan costs following a $100 million Term Loan B prepayment.
- Operating cash flow from continuing operations increased to $91.5 million. Management cited lower interest and acquisition/integration cash payments; cash generation was partly offset by working-capital movements.
- Enrollment trends were mixed: Chamberlain session enrollment declined about 4%; Walden enrollment declined 9.2%; Medical and Veterinary enrollment increased 3.4%.
- Restructuring expense rose to $15.1 million from $3.1 million, mainly due to real-estate consolidations and related asset impairments. Business acquisition and integration expense fell to $8.4 million from $26.6 million.
Outlook, risks, contingencies, and unusual items
- No full-year revenue or earnings guidance is stated in the supplied filing text. Management projected fiscal 2023 capital spending of $50–$60 million and expected additional Walden integration costs during the rest of the fiscal year.
- Management said cash, operating cash generation, and available revolver capacity should fund operations and growth plans for the foreseeable future. It also cautioned that COVID-19 and related healthcare-market disruption could continue to weigh on enrollment, revenue, operating income, and EPS.
- Higher-education operations depend materially on Title IV and other financial aid. Walden remained on a month-to-month Temporary Provisional Program Participation Agreement, with an $84 million letter of credit and additional oversight. AUC, RUSM, and RUSVM also had provisional certifications; failure to meet requirements could affect Title IV eligibility and materially harm results and liquidity.
- The company expected its consolidated Department of Education financial-responsibility composite score to fall below 1.5 for fiscal 2022, though management did not expect the acquisition-related changes alone to cause a further fall below that level. Possible consequences include heightened cash monitoring, additional approvals, or a letter of credit.
- Adtalem disclosed pending matters including a Chamberlain biometric-privacy class action and Walden student litigation alleging misrepresentations in its DBA program. It stated it had reserved for probable, estimable losses; outcomes and potential impacts for matters without accruals were not predictable. The DeVry-related $44.95 million settlement fund remained in escrow, with payments anticipated in fiscal 2023.
- Discontinued operations recorded a $3.7 million net loss, including $3.4 million of DeVry-related costs, a $3.4 million loss from post-closing sale adjustments, and a $3.1 million tax benefit. The business divestitures had been completed in fiscal 2022.
- Variable-rate Term Loan B exposure: management estimated a 100-basis-point rate increase would add approximately $3.5 million of annual interest expense. The company expected to amend its credit agreement to transition from LIBOR to SOFR during fiscal 2023.
- An accelerated share repurchase concluded October 14, 2022; Adtalem paid $13.2 million in cash on November 2, 2022 to settle the final amount. No open-market repurchases occurred in the quarter.
Most important facts for investors to verify
- Confirm that the intended issuer is Adtalem Global Education Inc. and the relevant reporting period is the quarter ended September 30, 2022, not Covista Inc. or 2022 Q1.
- Assess whether the reported revenue growth and earnings recovery persist after separating Walden acquisition timing, purchase-accounting adjustments, and excluded non-GAAP items.
- Monitor enrollment at Chamberlain and Walden, and whether management’s COVID-related explanations translate into stabilization or recovery.
- Check Walden’s provisional Title IV status, the expected fiscal 2022 composite score, and the effect of any Department of Education action on cash availability or eligibility.
- Track debt paydown, floating-rate interest costs, covenant headroom, and the LIBOR-to-SOFR transition.
- Review the progress and potential financial exposure of the disclosed litigation, DeVry settlement administration, and ongoing restructuring and integration costs.